Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Treatment of severe hypoglycemia outside of the hospital setting is limited to intramuscular glucagon requiring reconstitution prior to injection. The current study examined the safety and dose-response relationships of a needle-free intranasal glucagon preparation in youth aged 4 to <17 years. RESEARCH DESIGN AND METHODS: A total of 48 youth with type 1 diabetes completed the study at seven clinical centers. Participants in the two youngest cohorts (4 to <8 and 8 to <12 years old) were randomly assigned to receive either 2 or 3 mg intranasal glucagon in two separate sessions or to receive a single, weight-based dose of intramuscular glucagon. Participants aged 12 to <17 years received 1 mg intramuscular glucagon in one session and 3 mg intranasal glucagon in the other session. Glucagon was given after glucose was lowered to <80 mg/dL (mean nadir ranged between 67 and 75 mg/dL). RESULTS: All 24 intramuscular and 58 of the 59 intranasal doses produced a ≥25 mg/dL rise in glucose from nadir within 20 min of dosing. Times to peak plasma glucose and glucagon levels were similar under both intramuscular and intranasal conditions. Transient nausea occurred in 67% of intramuscular sessions versus 42% of intranasal sessions (P = 0.05); the efficacy and safety of the 2- and 3-mg intranasal doses were similar in the youngest cohorts. CONCLUSIONS: Results of this phase 1, pharmacokinetic, and pharmacodynamic study support the potential efficacy of a needle-free glucagon nasal powder delivery system for treatment of hypoglycemia in youth with type 1 diabetes. Given the similar frequency and transient nature of adverse effects of the 2- and 3-mg intranasal doses in the two youngest cohorts, a single 3-mg intranasal dose appears to be appropriate for use across the entire 4- to <17-year age range.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mauras, N., Beck, R., Xing, D., Ruedy, K., Buckingham, B., Tansey, M., White, N. H., Weinzimer, S. A., Tamborlane, W., Kollman, C., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1746 · Cited by 204
Self-citationTsalikian, E., Fox, L., Weinzimer, S., Buckingham, B., White, N. H., Beck, R., Kollman, C., Xing, D., Ruedy, K., & Diabetes Research in Children Network (DirecNet) Study Group (2012) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2011.00837.x · Cited by 83
Self-citationFREYCHET, L. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92181-2 · Cited by 67 · cited 1×
“History of any prior severe hypoglycemic event 6 (33) 2 (11) 5 (42)”
BackgroundDiabetes Research in Children Network (DirecNet) Study Group (2009) · Diabetes Care · doi:10.2337/dc08-2298 · Cited by 61
Cited by
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Self-citationChiang, J. L., Maahs, D. M., Garvey, K. C., Hood, K. K., Laffel, L. M., Weinzimer, S. A., Wolfsdorf, J. I., & Schatz, D. (2018) · Diabetes Care · doi:10.2337/dci18-0023 · Cited by 509
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationEuropean Resuscitation Council Guidelines 2021: Paediatric Life Support
Van de Voorde, P., Turner, N. M., Djakow, J., de Lucas, N., Martinez-Mejias, A., Biarent, D., Bingham, R., Brissaud, O., Hoffmann, F., Johannesdottir, G. B., et al. (2021) · Resuscitation · doi:10.1016/j.resuscitation.2021.02.015 · Cited by 448
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Yale, J.-F., Dulude, H., Egeth, M., Piché, C. A., Lafontaine, M., Carballo, D., Margolies, R., Dissinger, E., Shames, A. R., Kaplowitz, N., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0460 · Cited by 88
“In contrast, a full single dose of nasal glucagon (3 mg) can be administered to children and adolescents, as well as adults.(16) In conclusion, administration of nasal glucagon is faster and has a much higher success rate for delivery of the full glucagon dose with fewer errors than injectable glucagon.”
BackgroundSelf-citationA systematic review on insulin overdose cases: Clinical course, complications and treatment options
Johansen, N. J., & Christensen, M. B. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12957 · Cited by 49
Novel preparations of glucagon for the prevention and treatment of hypoglycemia
Hawkes, C. P., De Leon, D. D., & Rickels, M. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1216-4 · Cited by 46
Self-citationGuzman, C. B., Dulude, H., Piché, C., Rufiange, M., Sadoune, A. A., Rampakakis, E., Carballo, D., Triest, M., Zhang, M. X., Zhang, S., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13134 · Cited by 28
Self-citationMatsuhisa, M., Takita, Y., Nasu, R., Nagai, Y., Ohwaki, K., & Nagashima, H. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14019 · Cited by 27
Pontiroli, A. E., & Tagliabue, E. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01483-y · Cited by 25
“…12 12 31 ± 2 31 ± 2 29 ± 6 29 ± 6 12 (100) 12 (100) Stenninger (1993)a SC 11 11 9 ± 2 9 ± 2 36 ± 6 40 ± 6 11 (100) 11 (100) Rickels (2016) IM 75 75 33 ± 12 33 ± 12 48 ± 8 49 ± 8 74 (99) 75 (100) Sherr (2016) IM 59 24 10 ± 10 10 ± 10 72 ± 8 72 ± 8 58 (98) 24 (100) Suico (2019)a IM 66 66 – – 59 ±…”
Christiansen, M. P., Cummins, M., Prestrelski, S., Close, N. C., Nguyen, A., & Junaidi, K. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002137 · Cited by 22
A New Role for Glucagon: From Secondary Hormone to Key Player
De Fano, M., Malara, M., Rucco, S., Manco, M., Fanelli, C. G., Bolli, G. B., & Porcellati, F. (2025) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104233 · Cited by 1
Metadata
- Authors
- Sherr, J. L., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Rickels, M. R., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Fox, L. A., Wadwa, R. P., Schatz, D. A., Nathan, B. M., Marcovina, S. M., Rampakakis, E., Meng, L., Beck, R. W., & for the T1D Exchange Intranasal Glucagon Investigators
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-02-16
- Volume
- 39
- Issue
- 4
- Pages
- 555-562
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2276228986
- Cited by
- 122
- References
- 5
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.